Black Diamond Therapeutics, Inc. 8-K

What Happened
On March 16, 2026, Black Diamond Therapeutics, Inc. (BDTX) announced its financial results for the year and the three months ended December 31, 2025. The company furnished a press release announcing those results as Exhibit 99.1 to a Current Report on Form 8-K filed the same day. The filing states the furnished information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated.

Key Details

• Date of filing/announcement: March 16, 2026.
• Reported periods: year and three months ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K signed by Brent Hatzis‑Schoch, Chief Operating Officer and General Counsel.

Why It Matters
This filing notifies investors that BDTX has publicly released its latest earnings and operating results; investors should review the Exhibit 99.1 press release for the specific financial figures (revenue, net loss/income, cash position, and any guidance or program updates). Because the release is furnished rather than “filed,” it has different legal treatment under the Exchange Act; but it remains the primary source for the company’s reported FY2025 and Q4 2025 operating and financial information.